Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

NCT ID: NCT02626338

Last Updated: 2023-12-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-29
• Study Completion Date: 2018-02-28

Brief Summary

The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.

Detailed Description

Open label, dose de-escalation, pilot trial of crenolanib with standard salvage chemotherapy. Subjects may receive up to 2 cycles of induction with standard salvage chemotherapy followed by crenolanib. Each arm will enroll approximately 24 patients (72 total); stratification to each arm will be per physician's choice

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A

• Mitoxantrone
• Cytarabine
• Crenolanib

Group Type: EXPERIMENTAL

Crenolanib

Intervention Type: DRUG

Mitoxantrone

Intervention Type: DRUG

Cytarabine

Intervention Type: DRUG

Arm B

• Fludarabine
• Cytarabine
• G-CSF
• Idarubicin
• Crenolanib

Group Type: EXPERIMENTAL

Crenolanib

Intervention Type: DRUG

Cytarabine

Intervention Type: DRUG

Fludarabine

Intervention Type: DRUG

G-CSF

Intervention Type: DRUG

Idarubicin

Intervention Type: DRUG

Arm C

• Mitoxantrone
• Etoposide
• Cytarabine
• Crenolanib

Group Type: EXPERIMENTAL

Crenolanib

Intervention Type: DRUG

Mitoxantrone

Intervention Type: DRUG

Cytarabine

Intervention Type: DRUG

Etoposide

Intervention Type: DRUG

Interventions

Crenolanib

Intervention Type: DRUG

Mitoxantrone

Intervention Type: DRUG

Cytarabine

Intervention Type: DRUG

Etoposide

Intervention Type: DRUG

Fludarabine

Intervention Type: DRUG

G-CSF

Intervention Type: DRUG

Idarubicin

Intervention Type: DRUG

Other Intervention Names

cytosine arabinoside; Etoposide phosphate; Fludarabine monophosphate

Eligibility Criteria

Inclusion Criteria

1. Confirmed diagnosis of AML, including treatment-related secondary AML (except prior MDS) according to World Health Organization (WHO) 2008 classification at treating institution

2. Subjects who are refractory* or who have relapsed** following first line AML therapy with cytarabine/anthracycline based chemotherapy, with or without a tyrosine kinase inhibitor. *Refractory to induction therapy is defined as never achieving CR, CRi or CRp (according to International Working Group criteria) after one line of intensive regimen for AML (re-induction, consolidation and/or transplant allowed) including at least one cytarabine containing induction block with a total dose no less than 700mg/m² per cycle and 3 days of an anthracycline with or without a TKI.

or

**First relapse is defined as untreated hematologic relapse (according to International Working Group criteria) after one line of intensive regimen for AML (re-induction, consolidation and/or transplant allowed) including at least one cytarabine containing induction block with a total dose no less than 700mg/m² per cycle and 3 days of an anthracycline with or without a TKI that induced a CR/CRi/CRp. Subjects are allowed to receive induction, consolidation, transplant and/or maintenance prior to achieving their first CR/CRi/CRp.

3. Subjects considered eligible for intensive chemotherapy

4. ECOG performance status ≤ 2

5. Age ≥ 18 years

6. Adequate liver function within 72 hours of enrollment, defined as:

• Normal total serum bilirubin
• ALT and AST ≤ 2.0 x ULN

7. Adequate renal function, defined as serum creatinine ≤ 1.5x ULN

8. Women of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours prior to enrollment "Woman of childbearing potential" is defined as any woman who has not undergone a hysterectomy and who has had menses at any time in the preceding 24 consecutive months

9. Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy) while on crenolanib and for 3 months following the last dose of crenolanib. Hormonal contraception alone is not an acceptable method of birth control for the purpose of this trial.

10. Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 3 month after the last dose of crenolanib).

11. Willing to adhere to protocol specific requirements 12. Following receipt of verbal and written information about the study, the subject must provide signed informed consent before any study related activity is carried out. 13. Clinically significant toxic effects of prior therapy (expect hydroxyuria) resolved to Grade ≤ 1 before the start of study.

Exclusion Criteria

1. < 5% blasts in blood or marrow at screening, except if measurable extramedullary AML is confirmed

2. Acute promyelocytic leukemia (APL)

3. Known clinically active CNS leukemia

4. Clinically active or unstable graft-versus-host disease (GvHD) requiring treatment which precludes administration of chemotherapy as defined in this protocol

5. Prior anti-leukemia therapy within 14 days of enrollment for classical cytotoxic agents, and within 5x the half-life for other investigational agents

• Prior use of hydroxyurea or isolated doses of cytarabine for palliation (i.e., control of WBC) are allowed but should be discontinued at least 24 hrs prior to enrollment.
• Other agents used strictly with palliative intent might be allowed during this period after discussing with principal investigator

6. Pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)

7. Known HIV infection.

8. Evidence of ongoing, uncontrolled systemic infection or an uncontrolled local infection requiring therapy at the start of study.

9. "Currently active" second malignancy (other than non-melanoma skin cancer, carcinoma in situ of the cervix or prostatic intraepithelial neoplasia within 1 year). Subjects are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within 1 year.

10. Concurrent participation in another therapeutic clinical trial.

11. Pregnant or breastfeeding women

12. Subjects of childbearing potential not willing to use adequate contraception during study and 3 months after last dose of crenolanib

13. Subject with uncontrolled cardiac disease including congestive heart failure class III or IV by the NYHA, unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months

14. Subject with concurrent severe and/or uncontrolled medical or psychiatric conditions that in the opinion of the investigator may impair the participation in the study or the evaluation of safety and/or efficacy

15. Inability to give an informed consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Arog Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Arkansas

Little Rock, Arkansas, United States

City of Hope Medical Center

Duarte, California, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Houston Methodist

Houston, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

ARO-011

Identifier Type: -

Identifier Source: org_study_id